Retatrutide (2026) Semaglutide Mechanism: GLP-1 receptor agonist FDA Status: Approved for diabetes and weight management Expected Weight Loss: 1520% body weight Administration: Weekly injection Onset: Appetite changes within first few weeks Cost: Membership pricing at Better Med Spa see plans Tirzepatide Mechanism: Dual GIP + GLP-1 receptor agonist FDA Status: Approved for diabetes and weight management Expected Weight Loss: Up to 22% body weight Administration: Weekly injection Onset: Often faster appetite suppression Cost: Membership pricing at Better Med Spa see plans Retatrutide Mechanism: Triple agonist (GLP-1 + GIP + Glucagon) FDA Status: NOT approved investigational only Expected Weight Loss: Early data suggests very potent effects (up to 24% in trials) Administration: Weekly injection (investigational protocols) Onset: Under investigation Cost: Not yet available What Are Semaglutide, Tirzepatide, and Retatrutide

Day, PharmD, PCCA Vice President of Clinical Services, and Matt Martin, PharmD, PCCA Clinical Compounding Pharmacist This article was updated: 04/26/2019 The 2013 Drug Quality and Security Act established criteria for what 503A pharmacies can use as active ingredients in human compounding
Interdigestive gastroduodenal motility and serum motilin levels in patients with idiopathic delay in gastric emptying
The latter is considered less efficient and may bring about toxic metabolic byproduct formation
Ghrelin-receptor GHRP appetite-driving GH pulse empty-stomach timing ~100 mcg GHRP selective GH release 23x daily 100300 mcg GHRH analog long-acting 12x weekly 12 mg GHRH analog short-acting 23x daily 100 mcg GHRH analog historical FDA approval daily 200300 mcg GHRH analog FDA-approved (lipodystrophy) daily 2 mg Growth factor preclinical daily 2050 mcg Immune & Immunomodulatory Peptides Compounds in this category are discussed for immune coordination, inflammatory balance, and adjunctive immune support